Randomised Study of Casodex 50 Mg Monotherapy vs Orchidectomy in the Treatment of Metastatic Prostate Cancer

REFERENCES

• Andriole GL. Serum prostate-specific antigen: the most useful tumor marker. J Clin Oncol 1992; 10: 1205–1207.
   PubMed Web of Science ®Google Scholar
• Beland G, Elhilali M, Fradet Y, Laroche B, Ramsey EW, Trachtenberg J et al. A controlled trial of castration with and without nilutamide in metastatic prostate carcinoma. Cancer 1990; 66: 1074–1079.
   PubMed Web of Science ®Google Scholar
• Boccon-Gibod L, Fournier G, Bottet P, Marechal JM, Guiter J, Rischmann P, Hubert J, Soret JY, Mangin P, Mallo C. Flutamide versus orchidectomy in patients with metastatic prostate carcinoma. (Abstract 25) Proc 11th Congress of the European Association of Urology 1994.
   Google Scholar
• Chang A, Yeap B, Blum R, Hahn R, Khanna O, Fisher H, Witte R, Trump D. A double-blind randomised study of primary treatment for stage D2 prostate cancer; diethylstilbestrol (DES) versus flutamide. Proc Amer Soc Clin Oncol 1992; 11: 202.
   Google Scholar
• Blackledge G. Casodex—mechanisms of action and opportunities for usage. Cancer 1993; 72 (Suppl): 3830–3833.
   PubMedGoogle Scholar
• Delaere KPJ, Van Thillo EL. Flutamide monotherapy as primary treatment in advanced prostatic carcinoma. Semin Oncol 1992; 18 (Suppl 6): 13–18.
   Google Scholar
• Eri LM, Tveter KJ. A prospective, placebo-controlled study of the antiandrogen Casodex as treatment for patients with benign prostatic hyperplasia. J Urol 1993; 150: 90–95.
   PubMed Web of Science ®Google Scholar
• Furr BJA. Casodex: Preclinical studies. Eur Urol 1990; 18 (Suppl 3): 2–9.
   PubMedGoogle Scholar
• Huggins C, Hodges CV. Studies on prostate cancer. 1 The effect of castration, of estrogen and of androgen injection on serum phosphatase in metastatic carcinoma of the prostate. Cancer Res 1941; 1: 293–297.
   Google Scholar
• Jones GW. Magnitude of the problem. Cancer 1993; 71; 887–890.
   PubMedGoogle Scholar
• Iversen P. Update of clinical trials with the new antiandrogen, Casodex (ICI 176,334). Eur Urol 1994; 26 (Suppl 1): 5–9.
   PubMedGoogle Scholar
• Iversen P, Tveter K, Varenhorst E. Results of a Scandinavian multicentre open Phase III study of “Casodex” versus orchidectomy in the treatment of metastatic prostatic carcinoma. Proceedings of 3rd International Symposium on Recent Advances in Urological Cancer Diagnosis and Treatment, Paris 1992 ed Murphy G, Khoury S, Chatelain C, Denis L. Jersey, Scientific Communication International 1993.
   Google Scholar
• Kaisary AV. Current clinical studies with a new nonsteroidal antiandrogen, Casodex. Prostate 1994; (Suppl 5): 27–33.
   Google Scholar
• Kaisary AV, Tyrrell CJ, Beacock C, Lunglmayr G, Debruyne F. “Casodex”—an acceptable monotherapy for advanced prostate cancer? Preliminary results of a randomised trial against castration. In: Urology 1992 ed Giulioni L, Puppo P, Genoa 1992: 587–590.
   Google Scholar
• McLeod DG. Antiandrogenic drugs. Cancer 1993; 71: 1056–1059.
   Web of Science ®Google Scholar
• Migliari R, Muscas G, Usai E. Effect of Casodex on sleep-related erections in patients with advanced prostate cancer. J Urol 1992; 158: 338–351.
   Google Scholar
• Schröder FH, Boyle P. Screening for prostate cancer—necessity or nonsense? Eur J Cancer 1993; 29A: 656–661.
   PubMed Web of Science ®Google Scholar
• Schellhammer P, Sharifi R, Block N, Soloway M, Venner P, Patterson AL, Sarosdy M, Vogelzang N, Jones J, Kolvenbag G. A controlled trial of bicalutamide versus flutamide, each in combination with luteinzing hormone-releasing hormone analogue therapy, in patients with advanced prostate cancer. Urology 1995; 45: 745–752.
   PubMed Web of Science ®Google Scholar
• Sharifi R, Chodak G, Venner P, Block N, Callahan-Squire M, Jones J. Casodex versus castration in treatment of stage D2 prostate cancer: prostate specific antigen (PSA) as a measure of outcome. Proc Amer Soc Clin Oncol 1993; 12: 251.
   Google Scholar
• Tyrrell CJ. Casodex: a pure non-steroidal antiandrogen used as monotherapy in advanced prostate cancer. Prostate 1992; Suppl 5: 97–105.
   Google Scholar
• Pfitzenmeyer P, Foucher P, Piard F, Coudert B, Braud ML, Gabez P, Lacroix S, Mabille J-P, Camus P. Nilutamide pneumonitis: a report on eight patients. Thorax 1992; 57: 622–627.
   Google Scholar
• Varenhorst E. Prostate cancer treatment: Tolerance of different endocrine regimens. In: Klosterhalfen H, ed. New Developments in Bioscience 4, Endocrine management of proatatic cancer. Berlin, New York: Walter Gruyter, 1988: 105–113.
   Google Scholar
• Vogelzang NJ, Kennealey GT. Recent developments in endocrine treatment of prostate cancer. Cancer 1992; 70: 966–976.
   PubMed Web of Science ®Google Scholar
• Wysowski DK, Freiman JP, Tourtelot JB, Horton ML. Fatal and non-fatal hepatotoxicity associated with flutamide. Ann Intern Med 1993; 118: 860–864.
   PubMed Web of Science ®Google Scholar